Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity.
about
Maintaining fluoroquinolone class efficacy: review of influencing factors.Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.Combinatorially-generated library of 6-fluoroquinolone analogs as potential novel antitubercular agents: a chemometric and molecular modeling assessment.Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.Prulifloxacin: a new antibacterial fluoroquinolone.Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureusGemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections.10 years' experience with the pneumococcal quinolone moxifloxacin.Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review.Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat.Quinolone-DNA interaction: sequence-dependent binding to single-stranded DNA reflects the interaction within the gyrase-DNA complex.Finafloxacin for the treatment of urinary tract infections.Synthesis and antiproliferative activity of quinolone nucleosides against the human myelogenous leukemia k-562 cell line.Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.Two fluoroquinolones and their combinations with hyaluronan: comparison of effects on canine chondrocyte culture.Characterization of Salmonella Typhimurium DNA gyrase as a target of quinolones.Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.Synthesis and Evaluation of Thiazolidine Amide and N-Thiazolyl Amide Fluoroquinolone Derivatives.Quantitative structure-activity relationship study of antitubercular fluoroquinolones.Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?In vitro Antibacterial Activity of 7-Substituted-6-Fluoroquinolone and 7-Substituted-6,8-Difluoroquinolone Derivatives.Synthesis and Antibacterial Activity of Some Novel 4-Oxopyrido[2,3-a]phenothiazines
P2860
Q30310427-936AFD77-17EC-44B1-9BED-B235FC85AE25Q33770013-24394ACB-AD70-4593-BBBC-3C4E57FE830BQ33990519-986359EF-F3A6-4662-B51C-5CF87C3D8AAAQ34278283-94D4F8AD-4BBF-4D31-9AA0-610529D741C9Q34564526-848AB4F9-02EE-4334-B31B-6334266B589DQ34725095-8E96B987-5E04-4DF5-8CC1-855FB0D59B69Q35798789-47F9E538-F9A6-429E-B8CC-D67927CFE633Q37120372-B132CC2E-9D59-4A2A-8AA0-545E88DAC051Q37409945-514D0C26-9C8C-400D-9D89-98B43EA0C402Q37577369-9B08A3A7-DD13-4BF6-987F-5E3548BD0231Q37579919-ECBE4CCE-B21A-47D6-B37D-FBBB4CD19E76Q37982661-95D437C3-75E8-4E64-8AD9-7369223A10C1Q38081184-925F20FD-DF1C-4A0C-A251-0434683AD688Q38357316-27DAA1D7-2244-4998-8BAA-C6A27141BE7BQ38526001-79BD7F82-EF77-4211-AA40-ADF1BB197EB5Q39084346-11E30561-264C-4EE6-95AA-12427D08D159Q39465570-C8CE931B-D470-4130-9F0E-23719D0029D3Q39652121-3CE35D82-3F94-4497-99B3-08D482B64E0CQ40758206-6D5EDC73-466B-4142-A61F-631AB3C4619DQ41670488-C15E2CE5-C50B-4770-9BA2-BDC179839479Q47101582-6068FD6F-587B-4767-88FC-96BE3257C470Q48250022-BB991F1A-386E-4BBF-BFE7-8DBE9D523923Q51713941-6CB6FBB4-6161-46FF-A941-98692C580145Q52655525-135C3A2A-E987-49F0-945A-410FF7A9301EQ53407262-6A6DD5DA-2CDB-4E85-A26A-592006C8EC7CQ57787870-6A77384E-824E-4834-86FB-D2CCE4BBB3BC
P2860
Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Quinolone molecular structure- ...... roving antimicrobial activity.
@ast
Quinolone molecular structure- ...... roving antimicrobial activity.
@en
Quinolone molecular structure- ...... roving antimicrobial activity.
@nl
type
label
Quinolone molecular structure- ...... roving antimicrobial activity.
@ast
Quinolone molecular structure- ...... roving antimicrobial activity.
@en
Quinolone molecular structure- ...... roving antimicrobial activity.
@nl
prefLabel
Quinolone molecular structure- ...... roving antimicrobial activity.
@ast
Quinolone molecular structure- ...... roving antimicrobial activity.
@en
Quinolone molecular structure- ...... roving antimicrobial activity.
@nl
P2860
P356
P1476
Quinolone molecular structure- ...... roving antimicrobial activity.
@en
P2093
Peterson LR
P2860
P304
P356
10.1086/321846
P407
P478
33 Suppl 3
P577
2001-09-01T00:00:00Z